MEN1相关内分泌肿瘤的治疗:三项系统综述与一项荟萃分析
本研究针对多发性内分泌腺瘤病1型(MEN1)相关肿瘤的三个临床问题开展三项系统综述和一项荟萃分析。结果显示:甲状旁腺次全切除术较小于次全切除术降低持续性及复发性原发性甲状旁腺功能亢进风险,但术后甲状旁腺功能减退风险更高;对于≤2 cm无功能胰腺神经内分泌肿瘤,主动监测与手术的转移和死亡率相当;MEN1患者的泌乳素瘤对多巴胺激动剂的反应与非MEN1患者相似。所有证据的GRADE确定性均为低或极低。
要点
- 甲状旁腺次全切除术较小于次全切除术降低持续性和复发性原发性甲状旁腺功能亢进风险,但术后甲状旁腺功能减退风险更高。
- 对于≤2 cm无功能胰腺神经内分泌肿瘤,手术与主动监测的转移和死亡率相当,但证据来自少数队列研究。
- MEN1患者的泌乳素瘤对多巴胺激动剂的反应与非MEN1患者相似。
核心结论
- 在MEN1患者中,甲状旁腺次全切除术较小于次全切除术更大程度降低原发性甲状旁腺功能亢进的持续和复发,但术后甲状旁腺功能减退风险更高。
- 对于≤2 cm无功能胰腺神经内分泌肿瘤,现有少数研究提示主动监测可能与手术切除相当。
- 对于泌乳素瘤,多巴胺激动剂在MEN1患者中的疗效似乎与非MEN1患者相当。
研究设计与样本
- 三项系统综述和一项荟萃分析,检索MEDLINE Ovid、Embase Ovid、The Cochrane Library和Web of Science自2001年12月1日至2023年2月13日,无语言限制。
- 纳入随机对照试验、前瞻性和回顾性队列研究、病例对照研究和病例系列;纳入成人和儿童MEN1相关肿瘤患者。
- 三项系统综述前瞻性注册于PROSPERO(注册号CRD42023409912、CRD42023409936、CRD42023409949)。
主要发现
- Q1:23项研究共1073例患者,甲状旁腺次全切除术对比小于次全切除术,持续性原发性甲状旁腺功能亢进风险RR 0.32(95%CI 0.20-0.52;I²=0%),复发性原发性甲状旁腺功能亢进风险RR 0.78(95%CI 0.62-0.97;I²=27%),术后甲状旁腺功能减退风险RR 2.64(95%CI 1.63-4.29;I²=0%)。
- Q2:三项队列研究,手术组转移和死亡率合并为2/27(7%)至3/15(20%),主动监测组为1/33(3%)至4/50(8%),两组相当。
- Q3:十项研究共505例患者,MEN1患者多巴胺激动剂治疗失败率(血清泌乳素未正常化)为0/1至1/3(33%),非MEN1患者为4/68(6%)至9/11(82%),两组相似。
- 所有结局的GRADE证据确定性均为低或极低。
局限性
- 所有结局的GRADE证据确定性评分均为低或极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary disorder characterised by the combined occurrence of parathyroid, pancreatic, and pituitary tumours. Current treatments are based on very low-quality evidence. Our aims were to determine treatment outcomes in patients with MEN1 for: subtotal parathyroidectomy versus less than subtotal parathyroidectomy for primary hyperparathyroidism (Q1); surgery versus active surveillance for non-functioning pancreatic neuroendocrine tumours sized 2 cm or less (Q2); and dopamine agonist responses of prolactinomas in patients with MEN1 versus patients without MEN1 (Q3). METHODS: We conducted three systematic reviews and one meta-analysis. Four electronic databases (MEDLINE Ovid, Embase Ovid, The Cochrane Library, and Web of Science) were searched from Dec 1, 2001, to Feb 13, 2023, with no language restrictions. Study designs included randomised controlled trials, prospective and retrospective cohort studies, and case-controlled and case series. Adults and children with MEN1-associated tumours were included in all three systematic reviews. For each clinical question, three pairs of authors independently screened abstracts and assessed the full text for final inclusion, discordant views were resolved by senior authors. Dichotomous outcomes were calculated using risk ratios or hazard ratios for time-to-event analyses, with 95% CIs. Continuous outcomes were ascertained using mean difference with 95% CIs. Where feasible, outcomes from individual studies were analysed through meta-analysis, using a random-effects model. The systematic reviews were prospectively registered (PROSPERO reference numbers CRD42023409912, CRD42023409936, and CRD42023409949). FINDINGS: For primary hyperparathyroidism (Q1), 990 non-duplicate records were screened for title and abstract, of which 23 studies with 1073 patients were eligible for meta-analysis. These studies showed that subtotal parathyroidectomy had a significantly lower risk of persistent primary hyperparathyroidism (RR 0·32, 95% CI 0·20-0·52; I2=0%) and recurrent primary hyperparathyroidism (RR 0·78, 0·62-0·97; I2=27%), when compared with less than subtotal parathyroidectomy, although the risk of post-operative hypoparathyroidism was higher (RR 2·64, 1·63-4·29; I2=0%). For non-functioning pancreatic neuroendocrine tumours sized 2 cm and less (Q2), 1583 non-duplicate records were screened for title and abstract, of which three cohort studies were eligible for analysis. These studies showed that combined metastatic disease and mortality rates were comparable between patients in the surgery group (two [7%] of 27 to three [20%] of 15) and patients in the active surveillance group (one [3%] of 33 to four [8%] of 50]). For prolactinomas (Q3), 475 non-duplicate records were screened for title and abstract, of which ten studies with 505 patients were eligible for analysis. These studies showed that dopamine agonist treatment failure rates to normalise serum prolactin were similar between patients with MEN1 (zero of one to one [33%] of three) and patients without MEN1 (four [6%] of 68 to nine (82%) of 11), n=23 studies). GRADE certainty scores for all were low or very low. INTERPRETATION: In patients with MEN1, subtotal parathyroidectomy achieved greater reductions in persistence and recurrence of primary hyperparathyroidism than less than subtotal parathyroidectomy; for non-functioning pancreatic neuroendocrine tumours sized 2 cm or less, the few available studies suggest that active surveillance might be comparable to surgical resection; and for prolactinomas, dopamine agonist therapy appears to have comparable efficacy as in patients without MEN1. FUNDING: None.
引用
- English KA, Pieterman CRC, Marini F, et al. Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis. Lancet Diabetes Endocrinol. 2025. PMID: 40523371. doi:10.1016/S2213-8587(25)00118-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。